Publications
2023
Scholarly publications
Samukange, W. T., Lu, T-A., Souverein, P. C., Gardarsdottir, H., & Mantel-Teeuwisse, A. K. (2023). Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase. Transfusion, 63(5), 982-992. https://doi.org/10.1111/trf.17336
Luijken, K., van Eekelen, R., Gardarsdottir, H., Groenwold, R. H. H., & van Geloven, N. (2023). Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5620
Meijboom, R. W., Barbier, L., Druedahl, L. C., Sarnola, K., Tolonen, H. M., Gardarsdottir, H., Egberts, A., & Giezen, T. J. (2023). Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2023.2189008
Hunt, N. B., Pajouheshnia, R., Salih, A., van Doorn, S., Souverein, P. C., Bazelier, M. T., Klungel, O. H., & Gardarsdottir, H. (2023). Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15708
Trials@Home Consortium (2023). Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus. Drug Discovery Today, 28(4), [103520]. https://doi.org/10.1016/j.drudis.2023.103520
Hempenius, M., Rijken, S., Groenwold, R. H. H., Hek, K., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2023). Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study. British Journal of Clinical Pharmacology, 89(1), 268-278. https://doi.org/10.1111/bcp.15472
Melis, E. J., Zwart-van Rijkom, J. E., Egberts, T. C., van den Bemt, B. J., Witteveen, P. O., & Gardarsdottir, H. (2023). The association between patient satisfaction with information and adherence to oral anticancer agents. Journal of Oncology Pharmacy Practice, 29(3), 637–645. https://doi.org/10.1177/10781552221077258
2022
Scholarly publications
Trials@Home Consortium (2022). A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials. Trials, 23(1), 1-12. [856]. https://doi.org/10.1186/s13063-022-06706-x
Trials@Home Consortium (2022). Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019-2020? A cross-sectional study in ClinicalTrials.gov. BMJ Open, 12(8). https://doi.org/10.1136/bmjopen-2022-063236
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Doevendans, E., Leufkens, H. G., & Gardarsdottir, H. (2022). Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences, 175, 1-8. [106227]. https://doi.org/10.1016/j.ejps.2022.106227
Trials@Home Consortium (2022). Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective. Clinical Pharmacology and Therapeutics, 112(2), 344-352. https://doi.org/10.1002/cpt.2628
Camacho-Arteaga, L. F., Gardarsdottir, H., Ibañez, L., Souverein, P. C., van Dijk, L., Hek, K., Vidal, X., Ballarín, E., & Sabaté, M. (2022). Indications related to antidepressant prescribing in the Nivel-PCD database and the SIDIAP database. Journal of Affective Disorders, 303, 131-137. https://doi.org/10.1016/j.jad.2022.02.001
Meijboom, R. W., Gardarsdottir, H., Egberts, T. C. G., & Giezen, T. J. (2022). Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs, 36(1), 27-39. https://doi.org/10.1007/s40259-021-00508-4
Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2022). Use of Real World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. Clinical Pharmacology and Therapeutics, 111(1), 310-320. https://doi.org/10.1002/cpt.2462
Sindahl, P., Ofori-Asenso, R., Hallgreen, C. E., Kemp, K., Gardarsdottir, H., & De Bruin, M. L. (2022). Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study. British Journal of Clinical Pharmacology, 88(3), 1379-1384. https://doi.org/10.1111/bcp.15080
Wang, T., McAuslane, N., Gardarsdottir, H., Goettsch, W. G., & Leufkens, H. G. M. (2022). Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies. Drug Discovery Today, 27(1), 347-353. https://doi.org/10.1016/j.drudis.2021.09.014
2021
Scholarly publications
Sabaté, M., Vidal, X., Ballarin, E., Rottenkolber, M., Schmiedl, S., Grave, B., Huerta, C., Martin-Merino, E., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjær, M., Andersen, M., De Bruin, M. L., Souverein, P., Klungel, O. H., ... Ibáñez, L. (2021). Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015). Frontiers in Pharmacology, 12, 1-14. [682890]. https://doi.org/10.3389/fphar.2021.682890
Samukange, W. T., Kluempers, V., Porwal, M., Mudyiwenyama, L., Mutoti, K., Aineplan, N., Gardarsdottir, H., Mantel-Teeuwisse, A. K., & Nuebling, C. M. (2021). Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal. BMC Health Services Research, 21(1), 1-12. [1258]. https://doi.org/10.1186/s12913-021-07235-0
Meijboom, R. W., Gardarsdottir, H., Becker, M. L., ten Wolde, S., Egberts, T. C. G., & Giezen, T. J. (2021). Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept. BioDrugs, 35(6), 765–772. https://doi.org/10.1007/s40259-021-00501-x
Meijboom, R. W., Gardarsdottir, H., Becker, M. L., de Groot, M. C. H., Movig, K. L. L., Kuijvenhoven, J., Egberts, T. C. G., Leufkens, H. G. M., & Giezen, T. J. (2021). Switching TNFα inhibitors: Patterns and determinants. Pharmacology Research and Perspectives, 9(4), 1-9. [e00843]. https://doi.org/10.1002/prp2.843
van den Ham, H. A., Souverein, P. C., Klungel, O. H., Platt, R. W., Ernst, P., Dell'Aniello, S., Schmiedl, S., Grave, B., Rottenkolber, M., Huerta, C., Martín Merino, E., León-Muñoz, L. M., Montero, D., Andersen, M., Aakjær, M., De Bruin, M. L., & Gardarsdottir, H. (2021). Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiology and Drug Safety, 30(10), 1339-1352. https://doi.org/10.1002/pds.5317
Hempenius, M., Groenwold, R. H. H., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2021). Drug exposure misclassification in pharmacoepidemiology: sources and relative impact. Pharmacoepidemiology and Drug Safety, 30(12), 1703-1715. https://doi.org/10.1002/pds.5346
Abdullah-Koolmees, H., Nawzad, S., Egberts, T. C. G., Vuyk, J., Gardarsdottir, H., & Heerdink, E. R. (2021). The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders. Therapeutic Advances in Psychopharmacology, 11, 1-12. https://doi.org/10.1177/20451253211027449
Zhang, Y., Souverein, P. C., & Gardarsdottir, H. (2021). DOAC drug interactions and risk of major bleeding. Drug and Therapeutics Bulletin, 59(5), 70. https://doi.org/10.1136/dtb.2021.000014
Sindahl, P., Overgaard-Steensen, C., Wallach-Kildemoes, H., De Bruin, M. L., Kjær, M. B. N., Kemp, K., & Gardarsdottir, H. (2021). A cross-sectional survey of knowledge pertaining to IV fluid therapy and hyponatraemia among nurses working at emergency departments in Denmark. International Emergency Nursing, 57, 1-8. [101010]. https://doi.org/10.1016/j.ienj.2021.101010
Luijken, K., Spekreijse, J. J., van Smeden, M., Gardarsdottir, H., & Groenwold, R. H. H. (2021). New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: a review of reporting practices. Pharmacoepidemiology and Drug Safety, 30(7), 960-974. https://doi.org/10.1002/pds.5258
Hunt, N. B., Gardarsdottir, H., Bazelier, M. T., Klungel, O. H., & Pajouheshnia, R. (2021). A Systematic Review of How Missing Data are Handled and Reported in Multi-Database Pharmacoepidemiologic studies. Pharmacoepidemiology and Drug Safety, 30(7), 819-826. https://doi.org/10.1002/pds.5245
van Hunsel, F., Peters, L., Gardarsdottir, H., & Kant, A. (2021). Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals. Drug Safety, 44, 589-600. https://doi.org/10.1007/s40264-021-01047-1
Hempenius, M., Groenwold, R. H. H., Souverein, P. C., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2021). Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology, 87(9), 3508-3517. https://doi.org/10.1111/bcp.14764
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., & Gardarsdottir, H. (2021). Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals, 69, 30-37. https://doi.org/10.1016/j.biologicals.2020.12.003
Trials@Home Consortium (2021). COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union. Clinical Pharmacology and Therapeutics, 109(6), 1517-1527. https://doi.org/10.1002/cpt.2225
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., & Gardarsdottir, H. (2021). Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel, Switzerland), 14(3), 1-14. [189]. https://doi.org/10.3390/ph14030189
Minnema, L. A., Giezen, T. J., Hoekman, J., Egberts, T. C. G., Leufkens, H. G. M., & Gardarsdottir, H. (2021). Regulatory safety learning driven by the mechanism of action: the case of TNF-α inhibitors. Clinical Pharmacology and Therapeutics, 110(1), 123-131. https://doi.org/10.1002/cpt.2127
PE, PV consortium H. Gardarsdottir (2021). Prescribers' compliance with Summary of Product Characteristics of dabigatran, rivaroxaban and apixaban - a European comparative drug utilization study. Basic & Clinical Pharmacology & Toxicology, 128(3), 440-454. https://doi.org/10.1111/bcpt.13517
https://dspace.library.uu.nl/bitstream/handle/1874/428439/Basic_Clin_Pharma_Tox_2020_Rottenkolber_Prescribers_compliance_with_summary_of_product_characteristics_of_dabigatran.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/428439/Basic_Clin_Pharma_Tox_2020_Rottenkolber_Prescribers_compliance_with_summary_of_product_characteristics_of_dabigatran.pdf?sequence=1
Souverein, P. C., van den Ham, H. A., Huerta, C., Merino, E. M., Montero, D., León-Muñoz, L. M., Schmiedl, S., Heeke, A., Rottenkolber, M., Andersen, M., Aakjaer, M., De Bruin, M. L., Klungel, O. H., & Gardarsdottir, H. (2021). Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology, 87(3), 988-1000. https://doi.org/10.1111/bcp.14450
Professional publications
Gardarsdottir, H., Goedecke, T., Pacurariu, A., & Morales, D. (2021). ENCePP Guide on Methodological Standards in Pharmacoepidemiology: 14.4. Methods for pharmacovigilance impact research. In ENCePP Guide on Methodological Standards in Pharmacoepidemiology: 14.4. Methods for pharmacovigilance impact research (pp. 99-108)
Koster, E., Philbert, D., & Gardarsdottir, H. (2021). Implementatie keuzetool zelfzorgapps blijkt lastig: Diabetes: Gebruik van apps bij ondersteuning van zelfmanagement. Pharmaceutisch Weekblad, 156(35), 14-15.
2020
Scholarly publications
Wang, T., McAuslane, N., Liberti, L., Gardarsdottir, H., Goettsch, W., & Leufkens, H. (2020). Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. Frontiers in Pharmacology, 11, [594549]. https://doi.org/10.3389/fphar.2020.594549
Opalska, A., Kwa, M., Leufkens, H., & Gardarsdottir, H. (2020). Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 25(45), 1-7. https://doi.org/10.2807/1560-7917.ES.2020.25.45.2000035
Coppens, D. G., Gardarsdottir, H., Bruin, M. L. D., Meij, P., Gm Leufkens, H., & Hoekman, J. (2020). Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regenerative Medicine, 15(8), 2015-2028. https://doi.org/10.2217/rme-2020-0008
https://dspace.library.uu.nl/bitstream/handle/1874/428437/rme_2020_0008.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/428437/rme_2020_0008.pdf?sequence=1
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., Vulto, A. G., van der Plas, M. R., & Gardarsdottir, H. (2020). Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. European Journal of Pharmaceutical Sciences, 154, [105501]. https://doi.org/10.1016/j.ejps.2020.105501
Sindahl, P., Overgaard-Steensen, C., Wallach-Kildemoes, H., De Bruin, M. L., Leufkens, H. G., Kemp, K., & Gardarsdottir, H. (2020). Are further interventions needed to prevent and manage hospital-acquired hyponatraemia? A nationwide cross-sectional survey of IV fluid prescribing practices. Journal of Clinical Medicine, 9(9), 1-16. [2790]. https://doi.org/10.3390/jcm9092790
Minnema, L. A., Giezen, T. J., Egberts, T. C. G., Leufkens, H. G. M., & Gardarsdottir, H. (2020). Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community. European Journal of Neurology, 27(7), 1250-1256. https://doi.org/10.1111/ene.14259
Coppens, D. G. M., Hoekman, J., De Bruin, M. L., Slaper-Cortenbach, I. C. M., Leufkens, H. G. M., Meij, P., & Gardarsdottir, H. (2020). Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy, 22(10), 592-600. https://doi.org/10.1016/j.jcyt.2020.04.092
Hempenius, M., Luijken, K., de Boer, A., Klungel, O., Groenwold, R., & Gardarsdottir, H. (2020). Quality of reporting of drug exposure in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety, 29(9), 1141-1150. https://doi.org/10.1002/pds.5020
Coppens, D. G., Gardarsdottir, H., van den Bogert, C. A., De Bruin, M. L., Leufkens, H. G., & Hoekman, J. (2020). Publication rates and reported results in a cohort of gene- and cell-based therapy trials. Regenerative Medicine, 15(1), 1215-1227. https://doi.org/10.2217/rme-2019-0066
Zhang, Y., Souverein, P. C., Gardarsdottir, H., van den Ham, H. A., Maitland-van der Zee, A. H., & de Boer, A. (2020). Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case-control study. British Journal of Clinical Pharmacology, 86(6), 1150-1164. https://doi.org/10.1111/bcp.14227
Samukange, W. T., Gardarsdottir, H., Leufkens, H. G. M., & Mantel-Teeuwise, A. K. (2020). Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries. Transfusion Medicine Reviews, 34(2), 94-100. https://doi.org/10.1016/j.tmrv.2019.10.005
Professional publications
Bekker, C. L., van den Bemt, B. J. F., Gardarsdottir, H., Egberts, A. C. G., & Bouvy, M. L. (2020). Geneesmiddelverspilling verminderen. Nederlands Tijdschrift voor Geneeskunde, 164.
https://dspace.library.uu.nl/bitstream/handle/1874/428095/d4812.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/428095/d4812.pdf?sequence=1
2019
Scholarly publications
Souverein, P. C., Van Den Ham, H. A., Huerta, C., Merino, E. M., Montero, D., León-Muñoz, L. M., Schmiedl, S., Rottenkolber, M., Andersen, M., Aakjær, M., De Bruin, M. L., Klungel, O. H., & Gardarsdottir, H. (2019). Risk of major bleeding associated with the use of direct oral anticoagulants compared to vitamin K antagonists in patients with atrial fibrillation: A European multicountry population-based cohort study. Pharmacoepidemiology and Drug Safety, 28(S2), 553-553. https://doi.org/10.1002/pds.4864
Pajouheshnia, R., Gardarsdottir, H., Platt, R., Toh, D., & Klungel, O. (2019). Analysis of data from distributed pharmacoepidemiologic networks. Pharmacoepidemiology and Drug Safety, 28(S2), 414. https://doi.org/10.1002/pds.4864
Bekker, C., Van Den Bemt, B. J., Egberts, A. C., Bouvy, M. L., & Gardarsdottir, H. (2019). Willingness of patients to use unused medications returned to the pharmacy by another patient. International Journal of Clinical Pharmacy, 41(1), 302-303. https://doi.org/10.1007/s11096-018-0759-9
Van Den Ham, H., Souverein, P., Klungel, O., Platt, R., Ernst, P., Dell'Aniello, S., Schmiedl, S., Grave, B., Rottenkolber, M., Huerta, C., Merino, E. M., León-Muñoz, L., Montero, D., Andersen, M., Aakjær, M., De Bruin, M., & Gardarsdottir, H. (2019). Risk of major bleeding associated with the use of individual direct oral anticoagulants compared to vitamin K antagonists in patients with non-valvular atrial fibrillation: A metaanalysis of results from multiple population based cohort studies using a common protocol in Europe and Canada. Pharmacoepidemiology and Drug Safety, 28(S2), 410-411. https://doi.org/10.1002/pds.4864
Rottenkolber, M., Schmiedl, S., Ibanez, L., Sabaté, M., Ballarín, E., Vidal, X., Leon-Munoz, L. M., Huerta, C., Martin Merino, E., Montero, D., Gasse, C., Andersen, M., Aakjær, M., De Bruin, M. L., Gerlach, R., Tauscher, M., Souverein, P. C., Van Den Ham, R., Klungel, O., & Gardarsdottir, H. (2019). Prescribers' compliance with SmPC recommendations for dabigatran, rivaroxaban, and Apixaban: A European comparative drug utilization study. Pharmacoepidemiology and Drug Safety, 28(S2), 148-149. https://doi.org/10.1002/pds.4864
Meijboom, R. W., Gardarsdottir, H., Becker, M. L., Egberts, T. C. G., Leufkens, H. G. M., & Giezen, T. J. (2019). TNF-alpha inhibitor treatment patterns in patients with rheumatic diseases and those with inflammatory bowel disease. Pharmacoepidemiology and Drug Safety, 28(S2), 265-265. https://doi.org/10.1002/pds.4864
Ibanez, L., Sabaté, M., Vidal, X., Ballarín, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Merino, E. M., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjaer, M., Andersen, M., De Bruin, M. L., Groenwold, R., ... Gardarsdottir, H. (2019). Incidence of direct oral anticoagulation use for non valvular atrial fibrillation and characteristics of users in six European countries (2008-2015): A cross-national drug utilization study. Pharmacoepidemiology and Drug Safety, 28(S2), 397. https://doi.org/10.1002/pds.4864
Sabaté Gallego, M., Ibáñez Mora, L., Vidal Guitart, X., Ballarin Alins, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Martin Merino, E., Montero, D., León-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjaer, M., Andersen, M., De Briun, M., Groenwold, R., ... Gardarsdottir, H. (2019). Adherence to direct oral anticoagulants in patients with non-valvular atrial fibrillation cross-national comparison in six european countries. European Journal of Clinical Pharmacology, 75, 27-28. https://doi.org/10.1007/s00228-019-02685-2
Hempenius, M., Luijken, K., De Boer, A., Klungel, O. H., Groenwold, R. H. H., & Gardarsdottir, H. (2019). Current practice in reporting exposure in pharmacoepidemiological studies. 428. Abstract from 35th International conference on Pharmacoepidemiology & therapeutic risk management., Philapdelphia, Pennsylvania, United States. https://doi.org/10.1002/pds.4864
Vlieland, N. D., van den Bemt, B. J. F., Wouters, H., Egberts, A. C. G., Bouvy, M., & Gardarsdottir, H. (2019). Associations between personality traits and adequate home storage of drugs in older patients. Psychology, Health and Medicine, 24(10), 1255-1266. https://doi.org/10.1080/13548506.2019.1634822
Camacho Arteaga, L. F., Gardarsdottir, H., Souverein, P., Van Dijk, L., Sabaté, M., Vidal, X., Ballarín, E., & Ibañez, L. (2019). Indications related to antidepressant drug prescribing in the elderly population during 2010-2015 in two primary care databases: the Netherlands and Catalonia (Spain). European Journal of Clinical Pharmacology, 75(suppl 1), 49-50. https://doi.org/10.1007/s00228-019-02685-2
Ibáñez, L., Sabaté, M., Vidal, X., Ballarin, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Martin Merino, E., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjær, M., Andersen, M., De Bruin, M. L., Groenwold, R., ... Gardarsdottir, H. (2019). Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross-national drug utilization study. British Journal of Clinical Pharmacology, 85(11), 2524-2539. https://doi.org/10.1111/bcp.14071
van Hunsel, F., Gardarsdottir, H., de Boer, A., & Kant, A. (2019). Measuring the impact of pharmacovigilance activities, challenging but important. British Journal of Clinical Pharmacology, 85(10), 2235-2237. https://doi.org/10.1111/bcp.14042
Hempenius, M., Groenwold, R. H. H., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2019). Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. Pharmacoepidemiology and Drug Safety, 28(12), 1563-1571. https://doi.org/10.1002/pds.4851
Minnema, L. A., Giezen, T. J., Souverein, P. C., Egberts, T. C. G., Leufkens, H. G. M., & Gardarsdottir, H. (2019). Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study. Drug Safety, 42(7), 887-895. https://doi.org/10.1007/s40264-018-00789-9
Bekker, C., van den Bemt, B., Egberts, T. CG., Bouvy, M., & Gardarsdottir, H. (2019). Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. BMJ Open, 9(5), [e024767]. https://doi.org/10.1136/bmjopen-2018-024767
Bekker, C. L., Gardarsdottir, H., Egberts, A. C. G., Molenaar, H. A., Bouvy, M. L., van den Bemt, B. J. F., & Hövels, A. M. (2019). What does it cost to redispense unused medications in the pharmacy? A micro-costing study. BMC Health Services Research, 19(1), [243]. https://doi.org/10.1186/s12913-019-4065-6
Wouters, H., Rhebergen, D., Vervloet, M., Egberts, A., Taxis, K., van Dijk, L., & Gardarsdottir, H. (2019). Distinct Profiles on Subjective and Objective Adherence Measures in Patients Prescribed Antidepressants. Drugs, 79(6), 647-654. https://doi.org/10.1007/s40265-019-01107-y
Ampadu, H. H., Asante, K. P., Bosomprah, S., Akakpo, S., Hugo, P., Gardarsdottir, H., Leufkens, H. G. M., Kajungu, D., & Dodoo, A. N. O. (2019). Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: A modified cohort event monitoring study in public health facilities in Ghana and Uganda. Malaria Journal, 18(36), [36]. https://doi.org/10.1186/s12936-019-2670-9
Bekker, C. L., Kalicharan, R. W., Melis, E. J., Gardarsdottir, H., van den Bemt, B. J. F., Bouvy, M. L., van Maarseveen, E. M., & Egberts, A. C. G. (2019). Redispensing of unused HIV post-exposure prophylaxis for medical students. Travel Medicine and Infectious Disease, 29, 82-83. https://doi.org/10.1016/j.tmaid.2019.02.005
Minnema, L. A., Giezen, T. J., Gardarsdottir, H., Egberts, T. C. G., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2019). Post-marketing dosing changes in the label of biologicals. British Journal of Clinical Pharmacology, 85(4), 715-721. https://doi.org/10.1111/bcp.13843
Bekker, C. L., Melis, E. J., Egberts, A. C. G., Bouvy, M. L., Gardarsdottir, H., & van den Bemt, B. J. F. (2019). Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. Research in Social and Administrative Pharmacy, 15(1), 100-105. https://doi.org/10.1016/j.sapharm.2018.03.064
Vlieland, N. D., van den Bemt, B., van Riet-Nales, D. A., Bouvy, M. L., Egberts, T., & Gardarsdottir, H. (2019). Actual versus recommended storage temperatures of oral anticancer medicines at patients' homes. Journal of Oncology Pharmacy Practice, 25(2), 382-389. https://doi.org/10.1177/1078155217741767
Professional publications
Koster, E., Philbert, D., & Gardarsdottir, H. (2019). Diabetespatiënt heeft hulp nodig bij keuze geschikte app: Zelfmanagement bij diabetes wordt als positief ervaren . Pharmaceutisch Weekblad, 17, 18-19.
2018
Scholarly publications
Orsel, K., Taipale, H., Tolppanen, A-M., Koponen, M., Tanskanen, A., Tiihonen, J., Gardarsdottir, H., & Hartikainen, S. (2018). Psychotropic drug use and psychotropic polypharmacy among persons with Alzheimer's disease. 294. Abstract from 34th International conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic. https://doi.org/10.1002/pds.4629
Minnema, L., Giezen, T., Souverein, P., Egberts, T., Leufkens, B., & Gardarsdottir, H. (2018). Exploring the association between monoclonal antibodies and depression and suicidal ideation and behavior: A vigibase study. Drug Safety, 41(11), 1197-1198. https://doi.org/10.1007/s40264-018-0719-2
Kant, A., Peters, L., Gardarsdottir, H., & Van Hunsel, F. (2018). Opportunities and pitfalls when measuring harm reduction through pharmacovigilance activities. Drug Safety, 41(11), 1106-1107. https://doi.org/10.1007/s40264-018-0719-2
Van Hunsel, F., Peters, L., Gardarsdottir, H., & Kant, A. (2018). Measuring the impact of pharmacovigilance activities on public health; Practical example of 3 signals. Pharmacoepidemiology and Drug Safety, 27, 511-512. https://doi.org/10.1002/pds.4629
Minnema, L. A., Giezen, T. J., Souverein, P. C., Egberts, T. C. G., Leufkens, H. G. M., & Gardarsdottir, H. (2018). Exploring the association between monoclonal antibodies and depression and suicidal ideation and behaviour: A VigiBase study. Pharmacoepidemiology and Drug Safety, 27, 50. https://doi.org/10.1002/pds.4629
Zhang, Y., De Boer, A., Gardarsdottir, H., Van Den Ham, H. A., Maitland-Van Der Zee, A. H., & Souverein, P. C. (2018). Concurrent use of DOACs and pharmacodynamic interacting drugs is associated with an increased risk of major bleeding compared with patients using DOACs alone: Nested case-control study in UK CPRD. Pharmacoepidemiology and Drug Safety, 27, 465-466. https://doi.org/10.1002/pds.4629
Hempenius, M., Gardarsdottir, H., De Boer, A., Klungel, O., & Groenwold, R. (2018). Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions on risk estimation. Pharmacoepidemiology and Drug Safety, 27, 7. https://doi.org/10.1002/pds.4629
Vlieland, N. D., Van Den Bemt, B. J. F., Bekker, C. L., Bouvy, M. L., Egberts, A. C. G., & Gardarsdottir, H. (2018). The compliance with drug storage recommendations of elderly patients. International Journal of Clinical Pharmacy, 40(1), 238-239. https://doi.org/10.1007/s11096-017-0565-9
Bekker, C. L., Gardarsdottir, H., Egberts, A. C. G., Bouvy, M. L., & van den Bemt, B. J. F. (2018). Pharmacists' Activities to Reduce Medication Waste: An International Survey. Pharmacy, 6(3), [94]. https://doi.org/10.3390/pharmacy6030094
Orsel, K., Taipale, H., Raatikainen, S., Lampela, P., Tolppanen, A-M., Koponen, M., Tanskanen, A., Tiihonen, J., Gardarsdottir, H., & Hartikainen, S. (2018). Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study. Journal of Clinical Psychopharmacology, 38(5), 494-497. https://doi.org/10.1097/JCP.0000000000000928
Orsel, K., Taipale, H., Tolppanen, A-M., Koponen, M., Tanskanen, A., Tiihonen, J., Gardarsdottir, H., & Hartikainen, S. (2018). Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease. European Neuropsychopharmacology, 28(11), 1260-1269. https://doi.org/10.1016/j.euroneuro.2018.04.005
Bekker, C. L., Gardarsdottir, H., Egberts, A., Bouvy, M., & van den Bemt, B. J. F. (2018). Pharmacists' activities to reduce medication waste: An international survey. 228. Abstract from 46th ESCP symposium on clinical pharmacy “Science meets practice: towards evidence-based clinical pharmacy services”, Heidelberg, Germany. https://doi.org/10.1007/s11096-017-0565-9
Vlieland, N. D., Van Den Bemt, B. J. F., van Riet-Nales, D. A., Bouvy, M. L., Egberts, A. C. G., & Gardarsdottir, H. (2018). Actual versus recommended storage temperatures of oral anticancer drugs. 296. Abstract from ESCP symposium on clinical pharmacy, Heidelberg, Germany. https://doi.org/10.1007/s11096-017-0565-9
Abdullah-Koolmees, H., Gardarsdottir, H., Egberts, T. C. G., Minnema, L. A., Elmi, K., Stoker, L. J., Vuyk, J., Goedhard, L. E., & Heerdink, E. R. (2018). Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study. Therapeutic Advances in Psychopharmacology, 8(8), 213-229. https://doi.org/10.1177/2045125318762373
Bekker, C., Gardarsdottir, H., Melis, E. J., Egberts, A. C., Bouvy, M. L., & Van Den Bemt, B. J. (2018). Quantity and economic value of unused oral cancer drugs among patients who discontinue their therapy. International Journal of Clinical Pharmacy, 40(3), 732. https://doi.org/10.1007/s11096-018-0637-5
Ampadu, H. H., Dodoo, A. N. O., Bosomprah, S., Akakpo, S., Hugo, P., Gardarsdottir, H., Leufkens, H. G. M., Kajungu, D., & Asante, K. P. (2018). Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA). Drug Safety, 41(9), 871-880. https://doi.org/10.1007/s40264-018-0667-x
Bekker, C. L., van den Bemt, B. J. F., Egberts, A. C. G., Bouvy, M. L., & Gardarsdottir, H. (2018). Patient and medication factors associated with preventable medication waste and possibilities for redispensing. International Journal of Clinical Pharmacy, 40(3), 704-711. https://doi.org/10.1007/s11096-018-0642-8
Bekker, C. L., Gardarsdottir, H., Molenaar, E., Bouvy, M., van de Bemt, B. J. F., & Hövels, A. (2018). Cost estimation of redispensing unused medicines that are returned to the pharmacy: A micro-costing study. International Journal of Clinical Pharmacy, 40(1), 217. https://doi.org/10.1007/s11096-017-0565-9
Vlieland, N. D., Nejadnik, M. R., Gardarsdottir, H., Romeijn, S., Sediq, A. S., Bouvy, M. L., Egberts, A. C. G., van den Bemt, B. J. F., & Jiskoot, W. (2018). The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. Pharmaceutical Research, 35(2), [42]. https://doi.org/10.1007/s11095-017-2341-x
Vlieland, N. D., van Den Bemt, B. J. F., Bekker, C. L., Bouvy, M. L., Egberts, T. C. G., & Gardarsdottir, H. (2018). Older Patients’ Compliance with Drug Storage Recommendations. Drugs and Aging, 35(3), 233-241. https://doi.org/10.1007/s40266-018-0524-8
Professional publications
Vlieland, N. D., Gardarsdottir, H., Egberts, A. C. G., Bouvy, M. L., & Van Den Bemt, B. J. F. (2018). Bewaren geneesmiddelen thuis gaat vaak niet goed: Mogelijke gevolgen voor kwaliteit en effectiviteit. Pharmaceutisch Weekblad, 153(47), 10-11. https://www.pw.nl/achtergrond/2018/bewaren-geneesmiddelen-thuis-gaat-vaak-niet-goed
https://dspace.library.uu.nl/bitstream/handle/1874/428404/2018_Vleiland_Bewaren_geneesmiddelen_thuis_gaat_vaak_niet_goed_PW_Pharmaceutisch_Weekblad.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/428404/2018_Vleiland_Bewaren_geneesmiddelen_thuis_gaat_vaak_niet_goed_PW_Pharmaceutisch_Weekblad.pdf?sequence=1
Bekker, C. L., Gardarsdottir, H., Egberts, T. C. G., Bouvy, M. L., & Van Den Bemt, B. J. F. (2018). Heruitgifte van ongebruikte geneesmiddelen: Een kwalitatief onderzoek onder stakeholders. Pharmaceutisch Weekblad, 153(1-2), 25-27. https://www.knmp.nl/resolveuid/6031edfda9cd4bb2a60500e60ddbfae0
2017
Scholarly publications
Gardarsdottir, H., Kant, A., De Bruin, M. L., Hallgren, C. E., Pan, G. D., & Way, D. (2017). How to measure the impact of pharmacovigilance activities on public health? Pharmacoepidemiology and Drug Safety, 26, 31. https://doi.org/10.1002/pds.4275
Minnema, L. A., Giezen, T. J., Gardarsdottir, H., Egberts, T. C. G., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2017). Post-marketing label changes in dosing information of biopharmaceuticals-different from small molecules? Pharmacoepidemiology and Drug Safety, 26, 606-607. https://doi.org/10.1002/pds.4275
Bekker, C. L., Gardarsdottir, H., Egberts, T., van de Bemt, B. J. F., & Bouvy, M. (2017). Unused medicines returned to community pharmacy: An analysis of medication waste and possibilities for redispensing. International Journal of Clinical Pharmacy, 39(1), 240. https://doi.org/10.1007/s11096-016-0404-4
Bekker, C. L., Gardarsdottir, H., Egberts, T. C. G., Bouvy, M. L., & van den Bemt, B. J. F. (2017). Redispensing of medicines unused by patients: a qualitative study among stakeholders. International Journal of Clinical Pharmacy, 39(1), 196-204. https://doi.org/10.1007/s11096-017-0424-8
Other output
Wouters, H., Hilmer, S., van Campen, J., Van Der Meer, H., Gardarsdottir, H., Schaap, L. A., Huisman, M., Denig, P., Taxis, K., & Rhebergen, D. (2017). Trajectories of long-term exposure to anticholinergic and sedative drugs: A latent class growth analysis. 21. Poster session presented at 13th International Congress of the European Union Geriatric Medicine Society, Nice, France. https://doi.org/10.1016/S1878-7649(17)30178-X
Vlieland, N. D., Van Den Bemt, B. J. F., Bekker, C. L., Bouvy, M. L., Egberts, T. C. G., & Gardarsdottir, H. (2017). Patient compliance with drug storage recommendations. Pharmacoepidemiology and Drug Safety, 26(S2), 516-517. [854]. https://doi.org/10.1002/pds.4275
2016
Scholarly publications
Bekker, C., Gardarsdottir, H., Egberts, A., Bouvy, M., & Van Den Bemt, B. (2016). Stakeholders' views on and their minimal requirements for redispensing unused medicines: A qualitative study. International Journal of Clinical Pharmacy, 38(6), 591. https://doi.org/10.1007/s11096-015-0240-y
van Dijk, S. M., Gardarsdottir, H., Wassenberg, M. W. M., Oosterheert, J. J., de Groot, M. C. H., & Rockmann, H. (2016). The High Impact of Penicillin Allergy Registration in Hospitalized Patients. Journal of Allergy and Clinical Immunology: In Practice, 4(5), 926-931. https://doi.org/10.1016/j.jaip.2016.03.009
Abdullah, H., Gardarsdottir, H., Yazir, D., Stoker, L. J., Vuyk, J., Egberts, T. C. G., & Heerdink, E. R. (2016). Zorgen om medicatiegebruik psychiatrische patient na ontslag: Bijna 70% patiënten stopt met een of meer geneesmiddelen. Pharmaceutisch Weekblad, 151(7), 14-15. https://www.pw.nl/achtergrond/2016/zorgen-om-medicatiegebruik-psychiatrische-patient-na-ontslag
https://dspace.library.uu.nl/bitstream/handle/1874/428405/2016_Abdullah_Zorgen_medicatiegebruik_ontslag_psychiatrie_PW.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/428405/2016_Abdullah_Zorgen_medicatiegebruik_ontslag_psychiatrie_PW.pdf?sequence=1
Wouters, H., Amin, D. F. H., Taxis, K., Heerdink, E. R., Egberts, A. C. G., & Gardarsdottir, H. (2016). Associations between personality traits and adherence to antidepressants assessed through self-report, electronic monitoring, and pharmacy dispensing data: A Pilot Study. Journal of Clinical Psychopharmacology, 36(5), 465-471. https://doi.org/10.1097/JCP.0000000000000541
Klungel, O. H., Kurz, X., de Groot, M. C. H., Schlienger, R. G., Tcherny-Lessenot, S., Grimaldi, L., Ibáñez, L., Groenwold, R. H. H., Reynolds, R. F., Alvarez, Y., Candore, G., Durand, J., Slattery, J., Hasford, J., Rottenkolber, M., Schmiedl, S., de Abajo Iglesias, F., Gil, M., Gonzalez, R., ... On behalf of the members of work-package 2 of PROTECT (2016). Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project. Pharmacoepidemiology and Drug Safety, 25(supplement S1), 156-165. https://doi.org/10.1002/pds.3968
De Groot, M. C. H., Candore, G., Uddin, J., Souverein, P., Ali, M. S., Belitser, S., Huerta, C., Groenwold, R. H. H., Alvarez, Y., Slattery, J., Korevaar, J., Hoes, A. W., Roes, K. C. B., de Boer, A., Douglas, I. J., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2016). Case-only designs for studying the association of antidepressants and hip or femur fracture. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 103-113. https://doi.org/10.1002/pds.3850
Ali, M. S., Groenwold, R. H. H., Belitser, S., Souverein, P. C., Martín, E., Gatto, N. M., Huerta, C., Gardarsdottir, H., Roes, K. C. B., Hoes, A. W., de Boer, A., & Klungel, O. H. (2016). Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 25(Suppl 1), 114-121. https://doi.org/10.1002/pds.3864
Uddin, M. J., Groenwold, R. H. H., de Boer, A., Gardarsdottir, H., Martin, E., Candore, G., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Instrumental variables analysis using multiple databases: An example of antidepressant use and risk of hip fracture. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 122-131. https://doi.org/10.1002/pds.3863
Souverein, P. C., Abbing-Karahagopian, V., Martin, E., Huerta, C., de Abajo, F., Leufkens, H. G. M., Candore, G., Alvarez, Y., Slattery, J., Miret, M., Requena, G., Gil, M. J., Groenwold, R. H. H., Reynolds, R., Schlienger, R. G., Logie, J. W., de Groot, M. C. H., Klungel, O. H., van Staa, T. P., ... Gardarsdottir, H. (2016). Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. Pharmacoepidemiology and Drug Safety, 25 (Suppl 1), 88-102. https://doi.org/10.1002/pds.3862
Vlieland, N. D., Gardarsdottir, H., Bouvy, M. L., Egberts, T. C. G., & van den Bemt, B. J. F. (2016). The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology (Oxford, England), 55, 704-709. https://doi.org/10.1093/rheumatology/kev394
Requena, G., Logie, J., Martin, E., Boudiaf, N., González González, R., Huerta, C., Alvarez, A., Webb, D., Bate, A., García Rodríguez, L. A., Reynolds, R., Schlienger, R., Gardarsdottir, H., de Groot, M., Klungel, O. H., de Abajo, F., & Douglas, I. J. (2016). Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. Pharmacoepidemiology and Drug Safety, 25(Suppl. S1), 79–87. https://doi.org/10.1002/pds.3822
Requena, G., Huerta, C., Gardarsdottir, H., Logie, J., González-González, R., Abbing-Karahagopian, V., Miret, M., Schneider, C., Souverein, P. C., Webb, D., Afonso, A., Boudiaf, N., Martin, E., Oliva, B., Alvarez, A., De Groot, M. C. H., Bate, A., Johansson, S., Schlienger, R., ... de Abajo, F. J. (2016). Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. Pharmacoepidemiology and Drug Safety, 25(Suppl. S1), 66–78. https://doi.org/10.1002/pds.3816
Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P. C., De Bruin, M. L., Slattery, J., De Groot, M. C. H., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., ... de Abajo, F. J. (2016). Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiology and Drug Safety, 25(S1), 56–65. https://doi.org/10.1002/pds.3825
2015
Scholarly publications
Vlieland, N. D., Gardarsdottir, H., Bouvy, M. L., Egberts, A. C., & Van Den Bemt, B. J. (2015). Majority of patients do not store their biological disease modifying antirheumatic drugs within recommended temperature range. Annals of the Rheumatic Diseases, 74, 710-711. https://doi.org/10.1136/annrheumdis-2015-eular.3074
Abbing-Karahagopian, V., Souverein, P. C., Korevaar, J. C., Leufkens, H. G. M., Egberts, T. C. G., Gardarsdottir, H., & De Bruin, M. L. (2015). Concomitant medication use and its implications on the hazard pattern in pharmacoepidemiological studies: Example of antidepressants, benzodiazepines and fracture risk. Epidemiology Biostatistics and Public Health, 12(3), [e11273]. https://doi.org/10.2427/11273
Thengilsdõttir, G., Pottegård, A., Linnet, K., Halldõrsson, M., Almarsdõttir, A. B., & Gardarsdõttir, H. (2015). Do patients initiate therapy? Primary non-adherence to statins and antidepressants in Iceland. International Journal of Clinical Practice, 69(5), 597-603. https://doi.org/10.1111/ijcp.12558
Uddin, J., Groenwold, R. H. H., Ali, M. S., Candore, G., De Groot, M. C. H., Souverein, P. C., Alvarez, Y., Belitser, S., Hoes, A. W., De Boer, A., Roes, K. C. B., Klungel, O. H., & Gardarsdottir, H. (2015). Application of the self-controlled case series design in pharmacoepidemiological studies: A cautionary note. European Journal of Epidemiology, 30(8), 903. https://doi.org/10.1007/s10654-015-0072-z
Uddin, M. J., Groenwold, R. H. H., Ali, M. S., Candore, G., De Groot, M. C. H., Souverein, P. C., Alvarez, Y., Belitser, S., Hoes, A. W., De Boer, A., Roes, K. C. B., Klungel, O., & Gardarsdottir, H. (2015). Impact of violations of the assumptions of the self-controlled case series design in pharmacoepidemiological studies: An example of antidepressants use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 24, 2-3. https://doi.org/10.1002/pds.3838
Abdullah, H., Gardarsdottir, H., Yazir, D., Stoker, L. J., Vuyk, J., Egberts, T. C. G., & Heerdink, E. R. (2015). Medication Discontinuation in Patients After Discharge From a Psychiatric Hospital. Annals of Pharmacotherapy, 49(10), 1085-95. https://doi.org/10.1177/1060028015593763
Ferrer, P., Sabaté, M., Ballarín, E., Rottenkolber, M., Schmiedl, S., Amelio, J., De Abajo, F., Ruigómez, A., Gil, M., Huerta, C., Gardarsdottir, H., Afonso, A., Klungel, O., De Groot, M., Schlinger, R., Reynolds, R., & Ibáñez, L. (2015). Measuring drug use: Differences between medical records and healthcare utilisation data bases. Clinical Therapeutics, 37(8), 75. https://doi.org/10.1016/j.clinthera.2015.05.216
2014
Scholarly publications
Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., De Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., De Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., De Groot, M. C. H., Klungel, O. H., ... De Bruin, M. L. (2014). Antidepressant prescribing in five European countries: Application of common definitions to assess the prevalence, clinical observations, and methodological implications. European Journal of Clinical Pharmacology, 70(7), 849-857. https://doi.org/10.1007/s00228-014-1676-z
Ali, MS., De Groot, M., Candore, G., Groenwold, R. H. H., Souverein, P. C., Alvarez, Y., Uddin, M. J., Hoes, A. W., De Boer, A., Klungel, O. H., & Gardarsdottir, H. (2014). Antidepressantuse and the risk of hip fracture: A self-controlled case series approach in two primary care databases. Pharmacoepidemiology and Drug Safety, 23, 385. https://doi.org/10.1002/pds.3701
Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P. C., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigómez, A., García Rodríguez, L. A., Johansson, S., ... De Abajo, F. J. (2014). Incidence rates and trends of hip/femur fractures in five European countries: Comparison using e-healthcare records databases. Calcified Tissue International, 94(6), 580-589. https://doi.org/10.1007/s00223-014-9850-y
Wouters, H., Bouvy, M. L., Van Geffen, E. C., Gardarsdottir, H., Stiggelbout, A. M., & Van Dijk, L. (2014). Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence. Patient Preference and Adherence, 8, 179-90. https://doi.org/10.2147/PPA.S53748
Gardarsdottir, H., Stoker, L. J., Vuyk, J., Egberts, T. C. G., Heerdink, E. R., & Abdullah, H. (2014). Discontinuation of somatic medication during psychiatric hospitalization. Annals of Pharmacotherapy, 48(11), 1415-24. https://doi.org/10.1177/1060028014544897
Wouters, H., Van Dijk, L., Van Geffen, E. C. G., Gardarsdottir, H., Stiggelbout, A. M., & Bouvy, M. L. (2014). Primary-care patients' trade-off preferences with regard to antidepressants. Psychological Medicine, 44(11), 2301–2308. https://doi.org/10.1017/S0033291713003103
Other output
Ali, M. S., De Groot, M., Candore, G., Groenwold, R. H. H., Souverein, P. C., Alvarez, Y., Uddin, M. J., Hoes, A. W., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2014). Antidepressant Use and the Risk of Hip Fracture: A Self-Controlled Case Series Approach in Two Primary Care Databases. Pharmacoepidemiology and Drug Safety, 23, 385-385.
Requena, G., Huerta, C., Gardarsdottir, H., Miret, M., Martin, E., Souverein, P. C., Schneider, C., Gonzalez-Gonzalez, R., Bate, A., Alvarez, Y., Montero, D., Garcia-Rodriguez, L. A., Reynolds, R., Schlienger, R. G., de Groot, M. C. H., Klungel, O. H., & de Abajo, F. J. (2014). Risk of Hip Fractures Associated with Benzodiazepines: Common Methodology But Different Results in a Multi-Site Cohort Study. The PROTECT Project. Pharmacoepidemiology and Drug Safety, 23(S1), 383-384. [715].
https://dspace.library.uu.nl/bitstream/handle/1874/304517/715xx.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/304517/715xx.pdf?sequence=1
Abbing-Karahagopian, V., Souverein, P., Martin, E., Huerta, C., de Abajo, F., Leufkens, H., Candore, G., Alvarez, Y., Slattery, J., Miret, M., Requena, G., Gil, M., Groenwold, R., Reynolds, R., Schlienger, R., de Groot, M., Klungel, O. H., van Staa, T., Egberts, T., ... Gardarsdottir, H. (2014). Understanding Inconsistent Results from Observational Pharmacoepidemiological Studies: the Case of Antidepressant Use and Risk of Hip Fracture. Pharmacoepidemiology and Drug Safety, 23, 36-36.
Souverein, P. C., & Gardarsdottir, H. (2014). (Non)availability of Dosage Instructions in Electronic Health Care Databases and Exposure (mis)classification: the Example of Antidepressants. Pharmacoepidemiology and Drug Safety, 23, 36-37.
Thengilsdottir, G., Pottegard, A., Almarsdottir, A. B., & Gardarsdottir, H. (2014). Do Patients Initiate Therapy? Primary Non-Adherence to Statins and Antidepressant in Iceland. Pharmacoepidemiology and Drug Safety, 23, 200-200.
Klungel, O., De Groot, M., Gardarsdottir, H., Brauer, R., Grimaldi-Bensouda, L., Kurz, X., Gasse, C., & Reynolds, R. (2014). Impact of methodological choices on findings from pharmacoepidemiological studies: Final results of the IMI-protect (pharmacoepidemiological research on outcomes of therapeutics by a European consortium) project. Pharmacoepidemiology and Drug Safety, 23(S1), 43. [78]. https://doi.org/10.1002/pds.3701
De Groot, M. C. H., Belitser, S. V., Souverein, P. C., Groenwold, R. H. H., Candore, G., Alvarez, Y., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2014). Impact of varying control moment selection in a case-crossover (CCO) study on antidepressant drug (AD) use and hip/femur fracture (HFF) in protect. Pharmacoepidemiology and Drug Safety, 23(S1), 407-408. [758]. https://doi.org/10.1002/pds.3701
Souverein, P. C., De Groot, M. C. H., Martin, E., Huerta, C., Candore, G., Alvarez, Y., Slattery, J., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2014). No impact of adjusting for lifestyle factors or general practice on risk estimates for the association between antidepressants and hip/femur fracture. Pharmacoepidemiology and Drug Safety, 23(S1), 384-385. [716]. https://doi.org/10.1002/pds.3701
Requena, G., Logie, J., González-González, R., Gardarsdottir, H., Afonso, A., Souverein, P. C., Merino, E. M., Boudiaf, N., Huerta, C., Bate, A., Alvarez, Y., García-Rodríguez, L. A., Reynolds, R., Schlienger, R. G., De Groot, M. C. H., Klungel, O. H., & De Abajo, F. J. (2014). Risk of hip fractures associated with benzodiazepines: Applying common protocol to a multi-database nested case-control study. The protect project. Pharmacoepidemiology and Drug Safety, 23, 44. [80]. https://doi.org/10.1002/pds.3701
Uddin, M. J., Groenwold, R. H. H., De Boer, A., Gardarsdottir, H., Martin, E., Candore, G., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). Instrumental variable analysis using multiple databases: An example of antidepressant use and risk of hip/femur fracture. Pharmacoepidemiology and Drug Safety, 23(S1), 30-31. [55]. https://doi.org/10.1002/pds.3701
Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Souverein, P. C., Gardarsdottir, H., Hoes, A. W., De Boer, A., & Klungel, O. H. (2014). Antidepressant use and risk of hip fracture: A comparison of marginal structural models, conventional regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 23(S1), 199. [377]. https://doi.org/10.1002/pds.3701
Ryan, P., Anderson, M., Schuemie, M., Burke, A., Haynes, K., Man, K., Gardarsdottir, H., & De Bruin, M. L. (2014). The common data model: Lessons from past projects and ongoing initiatives. Pharmacoepidemiology and Drug Safety, 23(S1), 361-362. https://doi.org/10.1002/pds.3701
2013
Scholarly publications
Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Montserrat, M., Gil, M., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlinger, R., de Groot, M., Klungel, O. H., van Staa, T. P., ... De Bruin, M. L. (2013). Antidepressant Prescribing in Five European Countries: Application of Common Methods to Assess the Variation in Prevalence. Pharmacoepidemiology and Drug Safety.
Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigomez, A., Garcia, L. A., Johanson, S., ... De Abajo, F. J. (2013). Trends in Incidence Rates (IR) of Hip/Femur Fractures in Five European Countries: A Comparison Using Electronic Health Care Records (e-HCR). Pharmacoepidemiology and Drug Safety, 22, 408-409.
Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P., Slattery, J., De Groot, M. C. H., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., Garcia, L. A., ... De Abajo, F. J. (2013). Prevalence of Use of Benzodiazepines and Related Drugs in Seven European Databases: A Cross-National Descriptive Study from the PROTECT-EU Project. Pharmacoepidemiology and Drug Safety, 22, 472-472.
Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., De Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Montserrat, M., Gil, M., Hesse, U., Requena, G., De Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlinger, R., De Groot, M. C. H., Klungel, O. H., Van Staa, T. P., ... De Bruin, M. L. (2013). Antidepressant prescribing in five european countries: Application of common methods to assess the variation in prevalence. Pharmacoepidemiology and Drug Safety, 22, 279-280. https://doi.org/10.1002/pds.3512
Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P., Slattery, J., De Groot, M. C. H., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., García, L. A., ... De Abajo, F. J. (2013). Prevalence of use of benzodiazepines and related drugs in seven european databases: A cross-national descriptive study from the protect-eu project. Pharmacoepidemiology and Drug Safety, 22, 472. https://doi.org/10.1002/pds.3512
Thengilsdottir, G., Gardarsdottir, H., Almarsdottir, A. B., McClure, C. B., & Heerdink, E. R. (2013). The association between lifting an administrative restriction on antidepressant dispensing and treatment patterns in Iceland. Health Policy, 111(2), 193-199. https://doi.org/10.1016/j.healthpol.2013.03.002
Abdullah-Koolmees, H., Gardarsdottir, H., Stoker, L. J., Vuyk, J., Egberts, A. C. G., & Heerdink, E. R. (2013). Prevalence of medication use for somatic disease in institutionalized psychiatric patients. Pharmacopsychiatry, 46(7), 274-280. https://doi.org/10.1055/s-0033-1354405
Abdullah-Koolmees, H., Gerbranda, T., Deneer, V. H. M., Tjoeng, M. M., De Ridder, A. J., Gardarsdottir, H., & Heerdink, E. R. (2013). Discontinuation of anticoagulant care during admission to a psychiatric hospital. European Journal of Clinical Pharmacology, 69(4), 1025-9. https://doi.org/10.1007/s00228-012-1398-z
Other output
Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Montserrat, M., Gil, M., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlinger, R., de Groot, M., Klungel, O. H., van Staa, T. P., ... De Bruin, M. L. (2013). Antidepressant Prescribing in Five European Countries: Application of Common Methods to Assess the Variation in Prevalence. Pharmacoepidemiology and Drug Safety, 22, 279-280.
De Groot, M. C. H., Schlienger, R., Reynolds, R., Gardarsdottir, H., Juhaeri, J., Hesse, U., Gasse, C., Rottenkolber, M., Schuerch, M., Kurz, X., & Klungel, O. H. (2013). Improving consistency in findings from pharmacoepidemiological studies: The IMI-protect (Pharmacoepidemiological research on outcomes of therapeutics by a European consortium) project. Pharmacoepidemiology and Drug Safety, 22(s1), 370. [738]. https://doi.org/10.1002/pds.3512
Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigómez, A., García, L. A., Johanson, S., ... De Abajo, F. J. (2013). Trends in incidence rates (IR) of hip/femur fractures in five european countries: A comparison using electronic health care records (E-HCR). Pharmacoepidemiology and Drug Safety, 22(s1), 408-409. [811]. https://doi.org/10.1002/pds.3512
2012
Other output
Thengilsdottir, G., Gardarsdottir, H., Almarsdottir, A. B., McClure, C. B., & Heerdink, E. R. (2012). Does Lifting an Administrative Restriction on Antidepressant Drug Prescribing Influence Treatment Patterns? Pharmacoepidemiology and Drug Safety, 21, 436-437.
Abdullah-Koolmees, H., Gardarsdottir, H., Stoker, L. S., Vuyk, J., Egberts, T. C. G., & Heerdink, E. R. (2012). Prevalence of Medication Use for Somatic Disease in Hospitalized Psychiatric Patients. Pharmacoepidemiology and Drug Safety, 21, 435-436.
Abdullah-Koolmees, H., Gerbranda, T., Deneer, V. H. M., Tjoeng, M. M., De Ridder, A. J. M., Gardarsdottir, H., & Heerdink, E. R. (2012). Discontinuation of Anticoagulant Care during Admission in a Psychiatric Hospital. Pharmacoepidemiology and Drug Safety, 21, 287-287.
Gardarsdottir, H., Sauer, B. C., Liang, H., Ryan, P., Klungel, O., & Reynolds, R. (2012). Transparent, reproducible and reusable research in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 21(S3), 197. [416]. https://doi.org/10.1002/pds.3324
Abbing-Karahagopian, V., Gardarsdottir, H., Souverein, P. C., Klungel, O. H., Leufkens, B. G. M., Egberts, T. C. G., & De Bruin, M. L. (2012). Timing of concomitant drug use in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety, 21(S3), 423. [914]. https://doi.org/10.1002/pds.3324
2011
Other output
Curkendall, S., Liang, H., Gardarsdottir, H., & Misra, A. (2011). Coding Algorithms for Defining Study Population in Database Studies; a Literature Review. Pharmacoepidemiology and Drug Safety, 20, S163-S163.
2010
Scholarly publications
Gardarsdottir, H., Egberts, T. C. G., & Heerdink, E. R. (2010). The association between patient-reported drug taking and gaps and overlaps in antidepressant drug dispensing. Annals of Pharmacotherapy, 44(11), 1755-1761. https://doi.org/10.1345/aph.1P162
Gardarsdottir, H., Souverein, P. C., Egberts, T. C. G., & Heerdink, E. R. (2010). Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. Journal of Clinical Epidemiology, 63(4), 422-7. https://doi.org/10.1016/j.jclinepi.2009.07.001
Gardarsdottir, H., Egberts, A. C. G., & Heerdink, E. R. (2010). Transitions from General Practitioner to Psychiatrist Care (or vice versa) during a first antidepressant treatment episode. Pharmacopsychiatry, 43(5), 179-183. https://doi.org/10.1055/s-0030-1249096
Gardarsdottir, H., Egberts, T. C. G., van Dijk, L., & Heerdink, E. R. (2010). Seasonal patterns of initiating antidepressant therapy in general practice in the Netherlands during 2002-2007. Journal of Affective Disorders, 122(3), 208-12. https://doi.org/10.1016/j.jad.2009.06.033
Other output
Gardarsdottir, H., Egberts, A. C. G., & Heerdink, E. R. (2010). Transitions from General Practitioner to Psychiatrist Care (Or Vice Versa) During a First Antidepressant Treatment Episode. S272, 643. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
2009
Scholarly publications
Gardarsdottir, H., Egberts, T. C., Stolker, J. J., & Heerdink, E. R. (2009). Gardarsdottir et al. Respond to "Assessing Treatment Effects With Observational Analyses". American Journal of Epidemiology, 170(3), 288-288. https://doi.org/10.1093/aje/kwp138
van Geffen, E. C. G., Gardarsdottir, H., van Hulten, R., van Dijk, L., Egberts, A. C. G., & Heerdink, E. R. (2009). Initiation of antidepressant therapy: do patients follow the GP's prescription? British Journal of General Practice, 59(559), 81-87. https://doi.org/10.3399/bjgp09X395067
Gardarsdottir, H., van Geffen, E. C. G., Stolker, J. J., Egberts, T. C. G., & Heerdink, E. R. (2009). Does the Length of the First Antidepressant Treatment Episode Influence Risk and Time to a Second Episode? Journal of Clinical Psychopharmacology, 29(1), 69-72. https://doi.org/10.1097/JCP.0b013e31819302b1
Gardarsdottir, H., Egberts, T. C., Stolker, J. J., & Heerdink, E. R. (2009). Duration of Antidepressant Drug Treatment and Its Influence on Risk of Relapse/Recurrence: Immortal and Neglected Time Bias. American Journal of Epidemiology, 170(3), 280-285. https://doi.org/10.1093/aje/kwp142
Gardarsdottir, H. (2009). Drug treatment episodes in pharmacoepidemiology - antidepressant use as a model. [Doctoral thesis 1 (Research UU / Graduation UU), Utrecht University]. Utrecht University.
https://dspace.library.uu.nl/bitstream/handle/1874/36021/gardarsdottir.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/36021/gardarsdottir.pdf?sequence=1
Gardarsdottir, H., Egberts, A. C. G., van Dijk, L., Sturkenboom, M. C. J. M., & Heerdink, E. R. (2009). An algorithm to identify antidepressant users with a diagnosis of depression from prescription data. Pharmacoepidemiology and Drug Safety, 18(1), 7-15. https://doi.org/10.1002/pds.1677
Other output
Gardarsdottir, H., Heerdink, E. R., & Egberts, A. C. G. (2009). Constructing Drug Treatment Episodes from Individual Dispensed Prescriptions: The Influence of the Gap-Length. Pharmacoepidemiology and Drug Safety, 18, S63.
2008
Other output
Gardarsdottir, H., Egberts, T. C. G., & Heerdink, E. R. (2008). Neglected and immortal time bias in observational studies: Antidepressant drug use and risk of relapse/recurrence. Pharmacoepidemiology and Drug Safety, 17, S135-S136.
Gardarsdottir, H., Egberts, T. C. G., van Dijk, L., Sturkenboom, M., & Heerdink, E. R. (2008). An algorithm to identify antidepressant users with a diagnosis of depression from prescription data. Pharmacoepidemiology and Drug Safety, 17, S1-S1.
Gardarsdottir, H., Egberts, A. C. G., van Dijk, C. E. M. J., Sturkenboom, M. C. J. M., & Heerdink, E. R. (2008). An Algorithm To Identify Antidepressant Users with a Diagnosis of Depression from Prescription Data. S1. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
2007
Scholarly publications
Bosman, A. A. P., Gardarsdóttir, H., Härmark, L., Lourenço, L. M., Wuliji, T., Bates, I., & Carter, S. (2007). Academic mobility in pharmacy faculty: An exploratory study. Pharmacy Education, 7(2), 177-181. https://doi.org/10.1080/15602210701256757
Gardarsdottir, H., Heerdink, E. R., van Dijk, L., & Egberts, A. C. G. (2007). Indications for antidepressant drug prescribing in general practice in the Netherlands. Journal of Affective Disorders, 98(1-2), 109-115. https://doi.org/10.1016/j.jad.2006.07.003
2006
Scholarly publications
Gardarsdottir, H., Heerdink, ER., & Egberts, ACG. (2006). Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiology and Drug Safety, 15(5), 338-343. https://doi.org/10.1002/pds.1223
Gardarsdottir, H., Heerdink, E. R., & Egberts, A. C. G. (2006). Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiology and Drug Safety, 15, 338-343.
https://dspace.library.uu.nl/bitstream/handle/1874/19727/egberts_06_Potential_bias.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/19727/egberts_06_Potential_bias.pdf?sequence=1
Other output
Gardarsdottir, H., Heerdink, E. R., van Dijk, L., & Egberts, A. C. G. (2006). Indications for antidepressant drug prescribing in general practice in the Netherlands. Pharmacoepidemiology and Drug Safety, 15, S163-S164.
Gardarsdottir, H., Heerdink, E. R., van Dijk, L., & Egberts, A. C. G. (2006). Indications for Antidepressant Drug Prescribing in General Practice in the Netherlands. S163. Abstract from Unknown event, Asilomar, USA.
2005
Other output
Gardarsdottir, H., Heerdink, E. R., & Egberts, A. C. G. (2005). Potential Bias in Pharmacoepidemiological Studies Due to the Length of the Drug Free Period: A Study on Antidepressant Drug Use in Adults in the Netherlands. S202. Abstract from Unknown event, Asilomar, USA.